Biohaven Announces 3-Year Results for Troriluzole in Spinocerebellar Ataxia Treatment
Portfolio Pulse from Benzinga Newsdesk
Biohaven Ltd. (NYSE:BHVN) announced positive 3-year results for troriluzole in treating Spinocerebellar Ataxia (SCA), showing significant slowing of disease progression. The study met its primary endpoint, and Biohaven plans to submit a New Drug Application to the FDA in Q4 2024.
September 23, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biohaven's 3-year study results for troriluzole in SCA treatment show significant efficacy, potentially leading to FDA approval. This could position Biohaven as a leader in SCA treatment, impacting its stock positively.
The positive results from the 3-year study of troriluzole in SCA treatment demonstrate significant efficacy, meeting the primary endpoint. This positions Biohaven to potentially receive FDA approval, which would be a major milestone for the company, likely leading to a positive impact on its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100